Use of recombinant factor VIIa in surgery in factor-VII-deficient patients

被引:52
作者
Ingerslev, J
Knudsen, L
Hvid, I
Tange, MR
Fredberg, U
Sneppen, O
机构
[1] AARHUS UNIV HOSP,DEPT ORTHOPAED SURG,DK-8200 AARHUS N,DENMARK
[2] AARHUS UNIV HOSP,DEPT NEUROSURG,DK-8200 AARHUS N,DENMARK
关键词
bleeding; factor VII; FVII deficiency; recombinant FVIIa; surgery;
D O I
10.1046/j.1365-2516.1997.00105.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients suffering from severe factor VII deficiency may present with serious bleeding problems. No clear guidelines exist regarding therapy in such patients in case of a large bleeding or surgery. Indeed, it has been postulated that some patients with severe factor VII deficiency may never present with overt bleeding problems. However, in factor-VII-deficient patients who have previously demonstrated a clinical tendency to bleed, surgery is expected to cause excessive bleeding. We present two females suffering from a severe factor VII deficiency (FVII:C < 0.01 U mL(-1)) with a distinct history of haemorrhagic diathesis. Due to recurrent bleeding in the past, or for circumstantial reasons, surgery was demanded over a 4-year period on a total of seven occasions. To assist haemostasis during and after joint surgery on five occasions and for embolization and subsequent removal of a large haemangioma of the occipital region, recombinant factor VIIa (NovoSeven) was utilized in doses approximating 20 mu g kg(-1) b.w. every 6 h beginning immediately before surgery and continued until 30 h to 13 days postoperatively, depending of the size of the respective procedure. Using this approach, we observed normal haemostasis, and there were no signs of excessive postoperative bleeding or wound haematoma. No adverse reactions or side-effects were observed, and there were no complaints or clinical signs indicative of thrombotic complications. As judged from the clinical course of these seven minor and major surgeries, recombinant factor VIIa appears to be highly efficaceous and safe in the treatment patients with severe factor VII deficiency undergoing surgery.
引用
收藏
页码:215 / 218
页数:4
相关论文
共 15 条
  • [1] BECH RM, 1995, THROMB HAEMOSTASIS, V73, P324
  • [2] PROPHYLAXIS AND THERAPY WITH FACTOR-VII CONCENTRATE (HUMAN) IMMUNE, VAPOR HEATED IN PATIENTS WITH CONGENITAL FACTOR-VII DEFICIENCY - A SUMMARY OF CASE-REPORTS
    COHEN, LJ
    MCWILLIAMS, NB
    NEUBERG, R
    ZINKHAM, W
    BAUER, K
    GRIBBLE, TJ
    GLOWALLA, MB
    BORSON, R
    PHILLIPS, MD
    KUNSCHAK, M
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1995, 50 (04) : 269 - 276
  • [3] A FACTOR-VII CONCENTRATE FOR THERAPEUTIC USE
    DIKE, GWR
    GRIFFITHS, D
    BIDWELL, E
    SNAPE, TJ
    RIZZA, CR
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1980, 45 (01) : 107 - 118
  • [4] DEEP VEIN-THROMBOSIS AND PULMONARY-EMBOLISM IN CONGENITAL FACTOR-VII DEFICIENCY
    GERSHWIN, ME
    GUDE, JK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1973, 288 (03) : 141 - 142
  • [5] HASSAN HJ, 1984, HAEMOSTASIS, V14, P244
  • [6] KELLEHER JF, 1986, AM J PEDIAT HEMATOL, V8, P318
  • [7] ARTHROPATHY AND SURGERY IN CONGENITAL FACTOR-VII DEFICIENCY
    KUZEL, T
    GREEN, D
    STULBERG, SD
    BARON, J
    [J]. AMERICAN JOURNAL OF MEDICINE, 1988, 84 (04) : 771 - 774
  • [8] Miano C, 1987, Minerva Pediatr, V39, P807
  • [9] Nakagawa K, 1990, Nihon Geka Gakkai Zasshi, V91, P771
  • [10] CONGENITAL DEFICIENCY OF FACTOR-VII IN SUBARACHNOID HEMORRHAGE
    PAPA, ML
    SCHISANO, G
    FRANCE, A
    NINA, P
    [J]. STROKE, 1994, 25 (02) : 508 - 510